Hyloris Pharmaceuticals

Hyloris Pharmaceuticals

Hyloris was co-founded by CEO Stijn Van Rompay and CBDO Thomas Jacobsen, both alumni of the Belgian generics company Docpharma and its successor Alter Pharma. The company emerged from the same network that produced Uteron Pharma, a women's-health innovator, and operates from Liege, Belgium. Its board is anchored by pharmaceutical veterans including Leon Van Rompay, founder of the listed generics firm Docpharma, and Revital Rattenbach, founding CEO of the clinical-stage biotech 4P Pharma. The company's strategy centers on reformulation and repurposing of approved molecules via the FDA's 505(b)(2) pathway and equivalent frameworks in Europe and other regions. Its declared pipeline spans cardiovascular, pain management, and infectious disease—28 disclosed programs including Sotalol IV for atrial fibrillation, Maxigesic IV for post-operative pain, and Podofilox Gel for HPV-related warts. Hyloris commercializes through licensing and co-development agreements with distribution partners rather than maintaining a direct sales organization, a structure that keeps fixed costs low while enabling simultaneous advancement of early-, mid-, and late-stage assets. The company has not disclosed total deployment or AUM, consistent with its operating-company rather than fund-manager posture. Hyloris is a Euronext Brussels-listed entity with a public-market capital structure, not a pooled investment vehicle. Its management committee of five—including CFO Christophe Maréchal, COO Dietmar Aichhorn, and CLO Ann De Jaeger—reports to a six-member board chaired by Stefan Yee. In mid-2024, Thomas Jacobsen stepped into a co-CEO role before returning to his CBDO position by November 2025, a leadership adjustment the company disclosed in its governance materials. The firm publishes an ESG report but does not identify affiliated foundations or co-investment clubs. Hyloris differs structurally from most pharma-developer peers in its reliance on abbreviated regulatory pathways to convert established molecules into patentable, differentiated products. While generic companies compete on price and novel-drug companies carry full clinical-trial risk, Hyloris occupies a middle lane—using known safety profiles to reduce development cost and time, then monetizing through royalty-bearing partnerships. Its 30-plus-asset pipeline, breadth of therapeutic coverage, and public-company transparency make it an unusual platform for investors seeking exposure to late-stage biotech cash flows without single-asset binary risk.